Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CODX |
---|---|---|
09:32 ET | 2259 | 0.94 |
09:39 ET | 136 | 0.9074 |
09:42 ET | 100 | 0.91 |
10:04 ET | 400 | 0.9196 |
10:13 ET | 100 | 0.92 |
10:22 ET | 693 | 0.92 |
10:27 ET | 200 | 0.916 |
10:38 ET | 100 | 0.9141 |
10:49 ET | 3050 | 0.9137 |
10:51 ET | 100 | 0.91 |
10:54 ET | 549 | 0.905099 |
11:00 ET | 100 | 0.9002 |
11:02 ET | 450 | 0.900853 |
11:03 ET | 200 | 0.905 |
11:12 ET | 10057 | 0.905 |
11:18 ET | 1100 | 0.905 |
11:20 ET | 1100 | 0.905 |
11:21 ET | 321 | 0.905 |
11:23 ET | 100 | 0.9026 |
11:34 ET | 1186 | 0.9002 |
11:38 ET | 1200 | 0.9025 |
11:39 ET | 2400 | 0.9026 |
11:41 ET | 223 | 0.9026 |
11:45 ET | 1200 | 0.9001 |
11:48 ET | 110 | 0.9018 |
11:50 ET | 2000 | 0.90255 |
11:52 ET | 6176 | 0.9099 |
12:01 ET | 409 | 0.9027 |
12:03 ET | 582 | 0.9027 |
12:06 ET | 100 | 0.9025 |
12:15 ET | 225 | 0.905051 |
12:21 ET | 552 | 0.9099 |
12:24 ET | 2210 | 0.9051 |
12:26 ET | 700 | 0.9028 |
12:30 ET | 5953 | 0.9051 |
12:32 ET | 100 | 0.9003 |
12:33 ET | 2400 | 0.90025 |
12:35 ET | 4000 | 0.9003 |
12:37 ET | 8453 | 0.8849 |
12:39 ET | 2832 | 0.8875 |
12:46 ET | 3345 | 0.8973 |
12:48 ET | 250 | 0.9003 |
12:50 ET | 5022 | 0.9 |
12:53 ET | 131 | 0.883501 |
12:55 ET | 100 | 0.9003 |
12:57 ET | 310 | 0.9003 |
01:00 ET | 10278 | 0.8908 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Co-Diagnostics Inc | 29.9M | -0.6x | --- |
T2 Biosystems Inc | 10.5M | -0.1x | --- |
Renalytix PLC | 28.4M | -0.3x | --- |
Medite Cancer Diagnostics Inc | 90.0 | 0.0x | --- |
Neuroone Medical Technologies Corp | 19.1M | -1.3x | --- |
Viveve Medical Inc | 4.3K | 0.0x | --- |
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $29.9M |
---|---|
Revenue (TTM) | $7.3M |
Shares Outstanding | 31.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.91 |
EPS | $-1.38 |
Book Value | $2.75 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 4.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -549.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.